Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.35 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.35 |
| ▸ | CCR4 | P51679 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467833 | 0.97 | AXL (0.47) | AXLL3MBTL3L3MBTL1KDRINSR | |
| SCHEMBL467792 | 0.93 | AXL (0.44) | AXLL3MBTL3L3MBTL1KDRINSR | |
| SCHEMBL467696 | 0.90 | AXL (0.43) | AXLL3MBTL1KDRINSRFGFR1 | |
| SCHEMBL27769653 | 0.90 | AXL (0.42) | AXLL3MBTL3L3MBTL1KDRINSR | |
| SCHEMBL467478 | 0.90 | AXL (0.42) | AXLKDRINSRALDH1A1MAPT | |
| SCHEMBL27790975 | 0.90 | AXL (0.47) | AXLKDRINSRHRH3ALDH1A1 | |
| SCHEMBL30090809 | 0.90 | AXL (0.47) | AXLKDRINSRHRH3ALDH1A1 | |
| SCHEMBL467688 | 0.88 | AXL (0.40) | AXLKDRINSRHRH3CSF1R | |
| SCHEMBL467749 | 0.87 | AXL (0.40) | AXLKDRINSRCSF1RCDK4 | |
| SCHEMBL468621 | 0.86 | L3MBTL3 (0.43) | AXLL3MBTL3L3MBTL1MBTD1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | claimed |
| CN-110551105-B | Substituted triazoles useful as AXL inhibitors | 里格尔制药公司 | 2022-10-18 | — | — | CN | claimed |
| CN-101622246-A | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | claimed |
| EP-2114955-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008083357-A1 | BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | WO | claimed |
| US-20240277707-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2024-08-22 | — | — | US | disclosed |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | BERGENBIO ASA (NO) | 2023-11-23 | — | — | US | disclosed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | disclosed |
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | disclosed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20150126514-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-05-07 | — | — | US | disclosed |
| US-8431594-B2 | Bridged bicyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| EP-2328888-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110105512-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| CN-101622246-A | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149397-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885L3MBTL3 1257/4885L3MBTL1 1772/4885 |
| US-20230372337-A1 | Combination Therapy Comprising an AXL Inhibitor | AXL, CD274, CD47 | AXL 1/4885L3MBTL3 521/4885L3MBTL1 761/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | AXL 2/4885L3MBTL3 937/4885L3MBTL1 1266/4885 |
| US-20110105512-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | ERBB2, AXL, ERBB3 | AXL 2/4885L3MBTL3 1851/4885L3MBTL1 1857/4885 |
| US-20110098274-A1 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | AXL 1/4885L3MBTL3 2154/4885L3MBTL1 2161/4885 |
| US-20150126514-A1 | BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, ERBB2, TYRO3 | AXL 1/4885L3MBTL3 2219/4885L3MBTL1 2156/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | AXL 3/4885L3MBTL3 1679/4885L3MBTL1 1076/4885 |
| US-20240277707-A1 | Combination Therapy with AXL Inhibitor and Immune Checkpoint Modulator or Oncolytic Virus | AXL, CD274, HAVCR2 | AXL 1/4885L3MBTL3 1257/4885L3MBTL1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.